Abstract
Objective To study the impact of group II pulmonary hypertension (PH) on the outcomes of patients admitted with ST-elevation Myocardial Infarction (STEMI), we conducted a nationwide retrospective cohort study.
Patients and Methods Using the National Inpatient Sample (NIS) Database from 2017 to 2020, a retrospective study of adult patients with a principal diagnosis of STEMI with a secondary diagnosis with or without group II PH according to ICD-10 codes. Several demographics, including age, race, and gender, were analyzed. The primary endpoint was mortality, while the secondary endpoints included cardiogenic shock, mechanical intubation, length of stay in days, and patient charge in dollars. Multivariate logistic regression model analysis was used to adjust for confounders, with a p-value less than 0.05 considered statistically significant.
Results The study included 27,020 patients admitted with a STEMI, 95 of whom had group II PH. The mean age for patients with and without PH was 66 and 67, respectively. In the PH group, 37% were females compared to 34% in the non-PH group. The in-hospital mortality rate was higher in the PH group (31.5% vs. 9.5%, P <.001, aOR 3.25, P <.023). The rates and adjusted odds of cardiogenic shock and mechanical ventilation were higher in the PH groups (aOR 1.12 aOR 2.16, respectively) but not statistically significant. Patients with PH had a longer length of stay and a higher total charge.
Conclusion Group II PH was associated with worse clinical and economic outcomes in heart failure patients admitted with STEMI.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
n/a
Funding Statement
no external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The HCUP datasets are publicly available and hence are considered exempt from full or expedited institutional review boards (IRB) review (Federal Regulations 45 CFR 46.101 (b).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Financial support and conflict of interest disclosure: The authors do not have financial or other conflict of interest to disclose.
Preprint Server Disclosure: This manuscript has not been submitted elsewhere.
Data Availability
A STATA log containing the manuscript's results is available upon request.
List of abbreviations
- AMI
- acute myocardial infarction
- CCI
- Charlson comorbidity index
- CKD
- chronic kidney disease
- DM
- Diabetes mellitus
- LV
- left ventricle
- PAP
- Pulmonary arterial pressure
- PH
- pulmonary hypertension
- MI
- myocardial infarction
- NSTEMI
- non-ST-elevation myocardial infarction
- RV
- right ventricle
- STEMI
- ST-elevation myocardial infarction
